GLYCOPYRRONIUM TOSYLATE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for GLYCOPYRRONIUM TOSYLATE (GLYCOPYRRONIUM TOSYLATE).
Competitive antagonist of muscarinic acetylcholine receptors (M1, M2, M3), inhibiting parasympathetic nerve impulses. Blocks the action of acetylcholine at autonomic effector sites innervated by postganglionic cholinergic nerves, reducing salivary, bronchial, and gastric secretions, and relaxing smooth muscle.
| Metabolism | Primarily excreted unchanged in urine and bile; minimal hepatic metabolism (not significantly via CYP450 enzymes). |
| Excretion | Renal: 85% unchanged; biliary/fecal: ~5% as metabolites and unchanged drug; elimination primarily via glomerular filtration and tubular secretion. |
| Half-life | Terminal elimination half-life: 0.6–1.2 hours in adults with normal renal function; prolonged in renal impairment (up to 3–4 hours). Clinically, duration of action is longer than half-life due to high receptor affinity. |
| Protein binding | ~40% bound to albumin; minimal binding to α1-acid glycoprotein. |
| Volume of Distribution | Vd: 0.4–0.6 L/kg (approximately 30 L in 70 kg adult); indicates distribution primarily into extracellular fluid and highly perfused tissues; limited CNS penetration due to quaternary ammonium structure. |
| Bioavailability | Oral: <5% (extensive first-pass metabolism); Inhalation: 10–15% (systemic absorption from lungs); IM: 90–100%. |
| Onset of Action | IV: 1 minute; IM: 15–30 minutes; Inhalation: 30–60 minutes (bronchodilation); Oral: not clinically relevant (rapidly degraded in GI tract). |
| Duration of Action | Duration: 6–8 hours for anticholinergic effects (e.g., reduced secretions, bronchodilation); shorter for cardiac effects (2–4 hours). Note: In anesthesia, vagolytic effects last 2–3 hours. |
Glycopyrronium tosylate: 1-2 mg orally 2-3 times daily; maximum 8 mg daily.
| Dosage form | CLOTH |
| Renal impairment | eGFR 30-59 mL/min: administer 50% of normal dose; eGFR <30 mL/min: administer 25% of normal dose. |
| Liver impairment | No specific adjustment recommended; use with caution in severe hepatic impairment (Child-Pugh C). |
| Pediatric use | Children 2-12 years: 0.04-0.1 mg/kg orally 3-4 times daily (maximum 8 mg/day). |
| Geriatric use | Elderly patients: start at low end of dosing range (1 mg twice daily) due to increased anticholinergic sensitivity. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for GLYCOPYRRONIUM TOSYLATE (GLYCOPYRRONIUM TOSYLATE).
| Breastfeeding | Excretion into breast milk is unknown; however, due to quaternary ammonium structure, transfer is likely low. The M/P ratio is not established. Caution should be exercised. The manufacturer recommends discontinuing nursing or the drug, considering importance to mother. |
| Teratogenic Risk | Glycopyrronium tosylate is a quaternary ammonium anticholinergic agent. Teratogenic risk data in humans are limited. Animal studies have not shown teratogenic effects at clinically relevant doses. In the first trimester, the drug is not recommended unless clearly necessary. During the second and third trimesters, uterine blood flow should be considered due to potential anticholinergic effects, though no specific fetal malformations are documented. Use only if potential benefit justifies risk. |
■ FDA Black Box Warning
Not applicable; no FDA black box warning for glycopyrronium tosylate.
| Serious Effects |
["Hypersensitivity to glycopyrronium or any component","Narrow-angle glaucoma","Obstructive uropathy (e.g., bladder neck obstruction due to prostatic hypertrophy)","Gastrointestinal obstruction (e.g., pyloric stenosis)","Paralytic ileus","Severe ulcerative colitis","Myasthenia gravis (relative contraindication)","Tachycardia secondary to thyrotoxicosis or cardiac insufficiency"]
| Precautions | ["Not recommended for use in patients with glaucoma, urinary retention, or gastrointestinal obstruction due to anticholinergic effects","Use with caution in patients with autonomic neuropathy, hyperthyroidism, coronary artery disease, congestive heart failure, or hiatal hernia associated with reflux esophagitis","May cause heat prostration in high environmental temperatures due to decreased sweating","May cause drowsiness or blurred vision; caution patients about operating machinery"] |
Loading safety data…
| Fetal Monitoring | Monitor maternal heart rate, blood pressure, and signs of anticholinergic toxicity (e.g., constipation, urinary retention, blurred vision). Fetal monitoring should include heart rate assessment, especially during prolonged use in third trimester due to potential uterine relaxation effects. No specific additional monitoring required. |
| Fertility Effects | No significant effects on fertility have been reported in animal studies. Human data are absent. Potential anticholinergic effects may theoretically impact reproductive function but are unlikely at standard doses. |